ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The BCR-ABL kinase inhibitor imatinib induces a complete hematologic and cytogenetic response in the majority of CML patients [3], but is unable to completely eradicate BCR-ABL-expressing leukemic cells, suggesting that LSCs are not eliminated.